Is EFTRW or JNJ a better dividend investment in 2026?

EFTRW currently yields 333333.33% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: EFTRW offers higher current income.

What is the dividend yield difference between EFTRW and JNJ?

EFTRW has a forward dividend yield of 333333.33% ($2.00/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 333329.97 percentage points.

Home › Compare › EFTRW vs JNJ

EFTRW vs JNJ: Dividend Comparison 2026

EFTRW yields 333333.33% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EFTRW wins by $8.099219044190773e+31M in total portfolio value

INVESTMENT

TIME HORIZON10 years

EFTRW

● Live price

333333.33%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8.099219044190773e+31M

Annual income

$80,944,421,463,343,720,000,000,000,000,000,000,000.00

Full EFTRW calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — EFTRW vs JNJ

📍 EFTRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EFTRW	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EFTRW + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EFTRW pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFTRW

Annual income on $10K today (after 15% tax)

$28,333,333.33/yr

After 10yr DRIP, annual income (after tax)

$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, EFTRW beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFTRW + JNJ for your $10,000?

EFTRW: 50%JNJ: 50%

100% JNJ50/50100% EFTRW

Portfolio after 10yr

$4.0496095220953863e+31M

Annual income

$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr

Blended yield

99.94%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EFTRW

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-13.6

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFTRW buys

JNJ buys

No recent congressional trades found for EFTRW or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEFTRWJNJ

Forward yield	333333.33% ✓	3.36%
Annual dividend / share	$2.00	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$8.099219044190773e+31M	$20.0K ✓
Annual income after 10y	$80,944,421,463,343,720,000,000,000,000,000,000,000.00 ✓	$827.78
Total dividends collected	$8.098906375781879e+31M ✓	$5.6K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Buy	Buy

Year-by-year: EFTRW vs JNJ ($10,000, DRIP)

Year	EFTRW Portfolio	EFTRW Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$33,344,033	$33,333,333.33	$10,676	$355.77	+$33.33M → EFTRW
2	$103,911,171,366	$103,875,493,250.26	$11,407	$389.39	+$103911.16M → EFTRW
3	$302,644,656,190,810	$302,533,471,237,448.00	$12,198	$426.53	+$302644656.18M → EFTRW
4	$823,817,797,451,856,400	$823,493,967,669,732,100.00	$13,056	$467.62	+$823817797451.84M → EFTRW
5	$2,095,836,995,961,804,000,000	$2,094,955,510,918,530,000,000.00	$13,987	$513.12	+$2095836995961804.00M → EFTRW
6	$4,983,251,920,823,462,000,000,000	$4,981,009,375,237,783,000,000,000.00	$14,998	$563.56	+$4983251920823461888.00M → EFTRW
7	$11,073,835,968,753,321,000,000,000,000	$11,068,503,889,198,040,000,000,000,000.00	$16,098	$619.52	+$1.1073835968753322e+22M → EFTRW
8	$22,999,277,308,531,336,000,000,000,000,000	$22,987,428,304,044,770,000,000,000,000,000.00	$17,295	$681.69	+$2.2999277308531335e+25M → EFTRW
9	$44,643,905,199,991,210,000,000,000,000,000,000	$44,619,295,973,271,085,000,000,000,000,000,000.00	$18,599	$750.82	+$4.464390519999121e+28M → EFTRW
10	$80,992,190,441,907,720,000,000,000,000,000,000,000	$80,944,421,463,343,720,000,000,000,000,000,000,000.00	$20,022	$827.78	+$8.099219044190773e+31M → EFTRW

EFTRW vs JNJ: Complete Analysis 2026

EFTRW — Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Full EFTRW Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this EFTRW vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFTRW vs SCHD EFTRW vs JEPI EFTRW vs O EFTRW vs KO EFTRW vs MAIN EFTRW vs ABBV EFTRW vs MRK EFTRW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.